The U.S. has approved the first vaccine for RSV, shots to protect older adults. The respiratory virus filled hospitals with wheezing babies last fall but also endangers seniors. After decades of failure in developing an RSV vaccine, the Food and Drug Adm
Vaccine against RSVThe invention provides a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.K·拉多塞维奇J·H·H·V·屈斯泰...
An RSV vaccine has been approved by the FDA and the CDC will hold a meeting on the new injections on Thursday.
参考资料: [1] GSK's RSV Vaccine Wins Adcomm Backing One Day after Pfizer,Retrieved March 3th, 2023 from https://www.biospace.com/article/fda-adcomm-backs-pfizer-s-rsv-shot/ [2] US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older...
Novavax RSV Vaccine Pipeline NIAID: VRC-317 (DS-Cav1) 在进行基于 RSV F 蛋白融合前构象开发的疫苗产品前,不得不提到“DS-Cav1”,也就是 NIAID 团队开发的第一个融合前构象的 RSV F 蛋白疫苗设计,并在临床上进行了概念验证。具体设计就不多说了。 VRC-317 (DS-Cav1)疫苗在临床 I 期概念验证中,展示...
Novavax RSV Vaccine Pipeline NIAID: VRC-317 (DS-Cav1) 在进行基于 RSV F 蛋白融合前构象开发的疫苗产品前,不得不提到“DS-Cav1”,也就是 NIAID 团队开发的第一个融合前构象的 RSV F 蛋白疫苗设计,并在临床上进行了概念验证。具体设计就不多说了。
2https://www.investors.com/news/technology/gsk-stock-jumps-after-beating-pfizer-moderna-to-the-rsv-vaccine-finish-line/ 3https://us.gsk.com/en-us/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 4https://www....
The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration. The vaccine, named Arexvy, will be given to people 60 years and older.
"This is our first EU-authorized RSV vaccine that not only protects older adults but also infants, already from birth," EU health commissioner Stella Kyriakides said. She noted that RSV in children was "a leading cause of hospitalization in the EU" and she looked forward to the 27 member ...
最新研究显示,尼塞韦单抗能显著降低 RSV 相关的下呼吸道感染住院率,减少病毒感染的发生和重症率,从而有效地保护婴幼儿的健康。尽管中国目前尚无针对 RSV 的 vaccine,公众对于这项新生物制剂的使用依然寄予厚望。随着该药物在全国范围内的推广使用,健康专家们期待借此推动儿童呼吸道疾病的防控工作,提高医疗服务的质量。